Your browser doesn't support javascript.
loading
Predicting the duration of action of ß2-adrenergic receptor agonists: Ligand and structure-based approaches.
Chiesa, Luca; Sick, Emilie; Kellenberger, Esther.
Afiliação
  • Chiesa L; Laboratoire d'Innovation Thérapeutique, Faculté de Pharmacie, UMR7200 CNRS Université de Strasbourg, 67400, Illkirch, France.
  • Sick E; Laboratoire de Conception et Application de Molécules Bioactives, Faculté de Pharmacie, UMR7199 CNRS Université de Strasbourg, 67400, Illkirch, France.
  • Kellenberger E; Laboratoire d'Innovation Thérapeutique, Faculté de Pharmacie, UMR7200 CNRS Université de Strasbourg, 67400, Illkirch, France.
Mol Inform ; 42(12): e202300141, 2023 Dec.
Article em En | MEDLINE | ID: mdl-37872120
ABSTRACT
Agonists of the ß2 adrenergic receptor (ADRB2) are an important class of medications used for the treatment of respiratory diseases. They can be classified as short acting (SABA) or long acting (LABA), with each class playing a different role in patient management. In this work we explored both ligand-based and structure-based high-throughput approaches to classify ß2-agonists based on their duration of action. A completely in-silico prediction pipeline using an AlphaFold generated structure was used for structure-based modelling. Our analysis identified the ligands' 3D structure and lipophilicity as the most relevant features for the prediction of the duration of action. Interaction-based methods were also able to select ligands with the desired duration of action, incorporating the bias directly in the structure-based drug discovery pipeline without the need for further processing.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Agonistas de Receptores Adrenérgicos beta 2 Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Agonistas de Receptores Adrenérgicos beta 2 Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article